Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?

Elena V. Demidova, Pooja Ghatalia, Sanjeevani Arora

Research output: Contribution to journalEditorial

2 Scopus citations
Original languageEnglish
Pages (from-to)149-150
Number of pages2
JournalEuropean Urology
Volume81
Issue number2
DOIs
StatePublished - Feb 2022

Keywords

  • Carcinoma, Renal Cell/drug therapy
  • DNA-Binding Proteins
  • Female
  • Humans
  • Immune Checkpoint Inhibitors
  • Kidney Neoplasms/drug therapy
  • Male
  • Poly(ADP-ribose) Polymerase Inhibitors/pharmacology
  • Transcription Factors

Fingerprint

Dive into the research topics of 'Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?'. Together they form a unique fingerprint.

Cite this